美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

279.16

+9.463.51%

盤後：279.160.00000.00%19:32 EDT

成交量：48.93萬

成交額：1.36億

市值：330.67億

市盈率：-75.38

高：279.88

開：272.99

低：272.22

收：269.70

資料載入中...

總覽公司新聞公告

衝擊八連陽！全市場孤品創新藥ETF天弘(517380)漲3.49%，年內漲超42%！高盛：中國創新藥板塊仍處於價值窪地階段

港股午評：恒指微漲0.07%，創新藥大漲，“反內卷”板塊再度活躍，餐飲類股走低

【港股異動 | 創新藥概念再度走強政策利好及BD預期雙輪驅動機構稱板塊當前估值仍具吸引力】智通財經APP獲悉，創新藥

港股異動丨創新藥繼續受資金追捧，三生製藥、康方生物、科倫博泰生物均超創歷史新高

港股異動 | 百濟神州(06160)再漲超6% DLL3/CD3雙特異性抗體塔拉妥單抗上市申報獲受理

【港股異動 | 百濟神州(06160.HK)再漲超6% DLL3/CD3雙特異性抗體塔拉妥單抗上市申報獲受理】智通財經A

DLL3/CD3雙特異性抗體塔拉妥單抗申報上市

百濟神州-U股價微跌0.56% 生物製藥板塊活躍度受關注

小細胞肺癌或將迎來首個BiTE新療法，百濟神州塔拉妥單抗申報上市

高管減持迪哲醫藥另一面：全球化戰略會是下個百濟神州嗎？【醫藥視界】

眼看要賺錢，資金為什麼減持百濟神州？

股市动态分析

百濟神州7月15日成交額為1.81億美元

醫藥股2025中報業績預告：53家淨利潤增長，42家預計虧損

生物制品圈

科創成長層改革推進券商系統升級及風險揭示書籤署有序展開

2025全球製藥50強排名揭曉，中國藥企表現亮眼！

【力勤資源(02245.HK)發盈喜預計中期股東應占溢利約為12億元至15億元同比增幅約為104.4%至155.5%

醫保商保雙目錄調整生物醫藥午後漲幅擴大榮昌生物漲逾8%

港A創新藥板塊午後加速上漲，創新藥ETF天弘(517380)漲超2%，位居同類行業ETF第一

港股午評：衝高回落！恒指微漲0.2%，藥品股繼續活躍大金融股多數低迷

30天通關！NMPA再掀審批革命

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":279.16,"timestamp":1752696000000,"preClose":269.7,"halted":0,"volume":489268,"hourTrading":{"tag":"盘后","latestPrice":279.16,"preClose":279.16,"latestTime":"19:32 EDT","volume":2064,"amount":576114.84,"timestamp":1752708724081},"delay":0,"floatShares":75541600,"shares":118450658,"eps":-3.70325,"marketStatus":"未開盤","change":9.46,"latestTime":"07-16 16:00:00 EDT","open":272.99,"high":279.88,"low":272.2156,"amount":136024713.91704,"amplitude":0.028418,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1752739200000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":269.7,"preHourTrading":{"tag":"盘前","latestPrice":273.98,"preClose":269.7,"latestTime":"09:28 EDT","volume":826,"amount":224803.55702,"timestamp":1752672480066},"postHourTrading":{"tag":"盘后","latestPrice":279.16,"preClose":279.16,"latestTime":"19:32 EDT","volume":2064,"amount":576114.84,"timestamp":1752708724081},"volumeRatio":1.422363,"impliedVol":0.4955,"impliedVolPercentile":0.8421},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.422363,"shares":118450658,"dividePrice":0,"high":279.88,"amplitude":0.028418,"preClose":269.7,"low":272.2156,"week52Low":146.87,"pbRate":"9.45","psRate":"7.92","week52High":287.88,"institutionHeld":0,"latestPrice":279.16,"eps":-3.70325,"divideRate":0,"volume":489268,"delay":0,"ttmEps":-3.70325,"open":272.99,"prevYearClose":184.71,"prevWeekClose":250.3,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":255.69,"twentyDayClose":264.42,"sixtyDayClose":230.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552203108","title":"衝擊八連陽！全市場孤品創新藥ETF天弘(517380)漲3.49%，年內漲超42%！高盛：中國創新藥板塊仍處於價值窪地階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2552203108","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552203108?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 13:32","pubTimestamp":1752730354,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["ONC","06978","399300","BK0239","BK7504","LU0307460666.USD","01548","LU0477156953.USD","LU2456880835.USD","YANG","LU0310800965.SGD","159938","LU2417539215.USD","BK0188","07226","159217","BK4559","BK1574","LU2471134879.HKD","02096","LU2237443895.HKD","688235","LU1894683348.USD","01477","LU1201861249.SGD","BK4534","LU0130517989.USD","515120","LU1868836591.USD","LU1668664300.SGD","002294","01530","688136","FDN","HK0000320264.USD","IE00B19Z3581.USD","IE00BZ08YS42.EUR","LU2750360997.AUD","09939","CXO","159982","CXO.AU","06160","159992","BK7095","HSCEI","HSTECH","01177","BK1191","HK0000320223.HKD"],"gpt_icon":0},{"id":"2552170895","title":"港股午評：恒指微漲0.07%，創新藥大漲，“反內卷”板塊再度活躍，餐飲類股走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2552170895","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552170895?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 12:01","pubTimestamp":1752724885,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MHGmain","07226","01810","BABA","09999","06160","01801","METmain","MCHmain","02555","688235","ALBmain","TCHmain","TCEHY","06978","ONC","QCmain","HGmain","MIUmain","02150","09618","159562","00981","399441","HSCEI","03690","HSI","HHImain","00700","159871","NTES","161726","000819.SH","JD","09926","BIDU","02157","01276","01364","YANG","02162","600276","HSTECH","02097","159992","03086","08496","MHImain","MPNGY"],"gpt_icon":0},{"id":"2552525172","title":"【港股異動 | 創新藥概念再度走強 政策利好及BD預期雙輪驅動 機構稱板塊當前估值仍具吸引力】智通財經APP獲悉，創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2552525172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552525172?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 10:17","pubTimestamp":1752718633,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ONC","BK1593","06160","09926","159992","01530","BK4526","02162","LU0588546209.SGD","AAPG","LU0348784397.USD","06855","LU0417516571.SGD","BK1574","BK1587","BK4139","BK1500","BK0239","BK1588","02157","LU0348783233.USD","06978","IE00BPRC5H50.USD","LU1720050803.USD","LU1794554557.SGD","688235","BK1583","LU2328871848.SGD","LU2488822045.USD","LU1969619763.USD","LU0307460666.USD","BK1161","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2552749174","title":"港股異動丨創新藥繼續受資金追捧，三生製藥、康方生物、科倫博泰生物均超創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2552749174","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552749174?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 10:08","pubTimestamp":1752718113,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","LU2456880835.USD","BK4526","LU2360032135.SGD","688235","01177","BK4559","IE00BPRC5H50.USD","LU0130517989.USD","LU0648001328.SGD","LU1720050803.USD","BK4614","HSTECH","ONC","YANG","07226","LU0106831901.USD","BK4566","BK1500","LU0128525689.USD","LU0307460666.USD","159992","BK1587","LU2488822045.USD","LU1162221912.USD","IE00B5MMRT66.SGD","09926","LU0348784397.USD","06978","LU1791807156.HKD","LU0162691827.USD","BK4207","BK4534","02157","LU0477156953.USD","IE00BZ08YR35.GBP","HSCEI","02162","01477","06160","BK1589","IE00BZ08YT58.USD","LU2417539215.USD","LU1201861249.SGD","01530","AAPG","LU2462157665.USD","159938","09939","BK4585"],"gpt_icon":0},{"id":"2552742401","title":"港股異動 | 百濟神州(06160)再漲超6% DLL3/CD3雙特異性抗體塔拉妥單抗上市申報獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2552742401","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552742401?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 09:58","pubTimestamp":1752717499,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州再涨超6%，截至发稿，涨6.28%，报176.1港元，成交额4.26亿港元。消息面上，7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。塔拉妥单抗作为同类首创的DLL3/CD3双特异性抗体，或将为小细胞肺癌患者的后线治疗带来突破性进展。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4526","BK0239","BK4139","LU2328871848.SGD","LU0588546209.SGD","BK1161","688235","LU0307460666.USD","ONC","BK1500","LU1969619763.USD","BK1583","06160"],"gpt_icon":0},{"id":"2552241174","title":"【港股異動 | 百濟神州(06160.HK)再漲超6% DLL3/CD3雙特異性抗體塔拉妥單抗上市申報獲受理】智通財經A","url":"https://stock-news.laohu8.com/highlight/detail?id=2552241174","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552241174?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 09:58","pubTimestamp":1752717499,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0588546209.SGD","LU0307460666.USD","BK4526","BK4139","LU1969619763.USD","BK1588","06160","ONC","BK1500","BK1161","688235","LU2328871848.SGD","BK1583","BK0239"],"gpt_icon":0},{"id":"2552179075","title":"DLL3/CD3雙特異性抗體塔拉妥單抗申報上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2552179075","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552179075?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 09:02","pubTimestamp":1752714127,"startTime":"0","endTime":"0","summary":"7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。塔拉妥单抗作为同类首创的DLL3/CD3双特异性抗体，或将为小细胞肺癌患者的后线治疗带来突破性进展。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717090448a44fb768&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717090448a44fb768&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CDE","LU1223083913.SGD","688235","LU1223082519.USD","BK4526","06160","ONC","LU1223082196.USD","BK4017"],"gpt_icon":0},{"id":"2552412721","title":"百濟神州-U股價微跌0.56% 生物製藥板塊活躍度受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2552412721","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552412721?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 01:56","pubTimestamp":1752688566,"startTime":"0","endTime":"0","summary":"百济神州-U7月16日收盘报239.94元，较前一交易日下跌0.56%。当日股价波动区间为237.79元至246.28元，成交金额达5.01亿元。该公司属于生物制品行业，专注于创新型分子靶向药物和肿瘤免疫药物的研发。作为一家全球性生物科技公司，百济神州在肿瘤治疗领域拥有多个在研产品管线。7月16日数据显示，百济神州-U主力资金净流出2927.45万元。该股当前总市值为3694.74亿元，流通市值276.06亿元。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","BK0239","06160"],"gpt_icon":0},{"id":"2551140802","title":"小細胞肺癌或將迎來首個BiTE新療法，百濟神州塔拉妥單抗申報上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2551140802","media":"新浪医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551140802?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 19:15","pubTimestamp":1752664513,"startTime":"0","endTime":"0","summary":"2025年7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。SCLC约占所有肺癌病例的15%,，其中大约70%的SCLC患者初始诊断时即为ES-SCLC。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK4139","BK4526","06160"],"gpt_icon":0},{"id":"2551576142","title":"高管減持迪哲醫藥另一面：全球化戰略會是下個百濟神州嗎？【醫藥視界】","url":"https://stock-news.laohu8.com/highlight/detail?id=2551576142","media":"投资者网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551576142?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 18:01","pubTimestamp":1752660075,"startTime":"0","endTime":"0","summary":"减持释放什么信号迪哲医药进入一个高层减持密集期。其中，吴清漪减持金额超1900万元，股份来源于股权激励及二级市场增持。截至目前，公司仍无控股股东、实际控制人。获批上市后，该药被成功纳入医保。公司表示，两款药品纳入医保目录后，销量大幅增加。最为市场熟知的，是百济神州的泽布替尼。受此因素，该药成功在欧美获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","688192","06160","BK4139","BK4526"],"gpt_icon":0},{"id":"2552215179","title":"眼看要賺錢，資金為什麼減持百濟神州？","url":"https://stock-news.laohu8.com/highlight/detail?id=2552215179","media":"股市动态分析","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552215179?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 16:52","pubTimestamp":1752655962,"startTime":"0","endTime":"0","summary":"近日，二季度陆股通数据出炉，北向资金减持百济神州717.19万股，对应市值达17.20亿元。近几年，百济神州大股东也在陆续减持。自2023年6月8日起，陪伴公司十一年的高瓴资本开始多次减持百济神州，通过集中竞价与大宗交易等方式，在2023年6月8日至2024年12月2日期间减持约2199.73万股，持股比例从10.61%减少至9.02%。2025年3月3日至4日，高瓴资本再度减持3224万股，持股比例降至6.66%。百悦泽已在全球70多个市场获批，共计超过18万例患者接受治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170142a44e5022&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170142a44e5022&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK0239"],"gpt_icon":0},{"id":"2551149731","title":"百濟神州7月15日成交額為1.81億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551149731","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551149731?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 12:39","pubTimestamp":1752640775,"startTime":"0","endTime":"0","summary":"美东时间2025年7月15日，百济神州成交额为1.81亿美元，成交额较昨日增加575.75%，当日成交量为67.44万股。百济神州于2025年7月15日涨6.96%，报269.7美元，该股过去5个交易日涨10.32%，年初至今涨46.01%，过去60日涨18.22%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716123942a44dcfb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716123942a44dcfb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2551114238","title":"醫藥股2025中報業績預告：53家淨利潤增長，42家預計虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=2551114238","media":"生物制品圈","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551114238?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 11:56","pubTimestamp":1752638187,"startTime":"0","endTime":"0","summary":"CRO龙头企业药明康德系披露业绩预告的医药股中，预告归属净利润最高的个股，公司预计上半年实现净利85.61亿元，同比预增101.92%。业绩亮点：2025 年中报归母净利润预计同比增长 145.67%~170.23%。0242股净利预计亏损东方财富Choice数据显示，按预告净利润下限统计，共有42只医药股预计2025年上半年将出现亏损。其中，达安基因、海南海药预计亏损金额居前。这也是联环药业自2003年上市以来首次半年度净利亏损。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716121157a6ac870d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716121157a6ac870d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","600513","688180","01877","01801","06160","600196","603259","603392","01276","SBHMY","600276","159938","02196","688235","01177"],"gpt_icon":0},{"id":"2551119280","title":"科創成長層改革推進 券商系統升級及風險揭示書籤署有序展開","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551119280?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作，并修订相关指南，新增《科创板科创成长层企业股票投资风险揭示书必备条款》，明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作，包括完成风险揭示书签署及系统准备，给予投资者充分阅读时间，并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日，上交所举办专题培训会，120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688702","688220","688322","688515","02402","ONC","688221","000690.SH","688256","688280","688387","688266","09969","BK0239","688343","688302","688538","688561","688192","688277","688176","688512","688197","688443","688316","688373","688549","688165","688469","01877","688327","688382"],"gpt_icon":0},{"id":"2551216032","title":"2025全球製藥50強排名揭曉，中國藥企表現亮眼！","url":"https://stock-news.laohu8.com/highlight/detail?id=2551216032","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551216032?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 19:46","pubTimestamp":1752580012,"startTime":"0","endTime":"0","summary":"近日，美国《制药经理人》杂志公布了2025全球制药企业50强排名。这一榜单依据2024年度处方药业务全球销售、核心产品收入以及研发投入等指标进行排名。中国药企上榜情况概览此次上榜的6家中国药企中，云南白药排名第33位，与去年持平，位居中国药企榜首。华东医药首次上榜，排名第41位。2025全球制药50强榜单中国药企的亮眼表现，是中国制药行业发展的一个重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715205051a44c7785&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715205051a44c7785&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","01276","01093","SBHMY","06160","688235","BK0239","01177","ONC"],"gpt_icon":0},{"id":"2551522231","title":"【力勤資源(02245.HK)發盈喜 預計中期股東應占溢利約為12億元至15億元 同比增幅約為104.4%至155.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551522231","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551522231?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 16:32","pubTimestamp":1752568374,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1190","MCNHmain","MUCmain","02245","BK4526","CYB","CNHmain","ONC","UCmain","BK4139"],"gpt_icon":0},{"id":"2551156152","title":"醫保商保雙目錄調整 生物醫藥午後漲幅擴大 榮昌生物漲逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551156152","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551156152?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 14:18","pubTimestamp":1752560315,"startTime":"0","endTime":"0","summary":"截至发稿，荣昌生物涨8.37%，石药集团涨7.26%，诺诚健华涨6.95%，百济神州涨6.43%，中国生物制药涨4.61%，信达生物涨3.66%。消息面上，2025年国家基本医疗保险，生育保险和工伤保险药品目录及商业健康保险创新药品目录调整7月11日正式启动。世纪证券指出，创新药商保目录意味着国内医药多元支付体系重构，商业健康险将在创新药支付方面扮演更为重要的角色，高价创新药可及性有望进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1008478684.HKD","LU0501845795.SGD","SG9999004220.SGD","BK1574","BK1191","IE0008368742.USD","LU1152091168.USD","LU0880133367.SGD","IE00BZ08YR35.GBP","LU1993786604.SGD","01177","LU0140636845.USD","LU1807302812.USD","LU1969619763.USD","LU1226288170.HKD","LU1226287792.SGD","688331","IE00B5MMRT66.SGD","688428","LU0315179316.USD","09995","09969","IE00B543WZ88.USD","01801","BK1583","LU1960683339.HKD","LU2328871848.SGD","06160","IE00BZ08YT58.USD","688235","IE00BZ08YS42.EUR","IE0008369823.USD","LU1226288253.USD","ONC","LU1152091754.HKD","SBHMY","BK1515","IE00B031HY20.USD","LU0072913022.USD","LU0067412154.USD","01093","LU1951186391.HKD","LU1226287529.USD","BK1521","BK1161","LU1226287875.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2551156989","title":"港A創新藥板塊午後加速上漲，創新藥ETF天弘(517380)漲超2%，位居同類行業ETF第一","url":"https://stock-news.laohu8.com/highlight/detail?id=2551156989","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551156989?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 14:13","pubTimestamp":1752559993,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1141","BK1500","07226","BK1576","688331","06160","BK4139","159646","BK4588","159938","688235","512290","09995","CXO","LU0307460666.USD","LU2495084118.USD","YANG","BK4550","159982","399441","02359","688428","399300","002755","159992","FDN","ONC","HSCEI","BK4585","09939","LU2328871848.SGD","BK1515","515120","LU0708995583.HKD","06978","161726","603259","BK1574","CXO.AU","159217","159859","300363","LU2125910500.SGD","BK1583","BK4614","09969","LU1997245177.USD","HSTECH","LU2045819591.USD"],"gpt_icon":0},{"id":"2551715870","title":"港股午評：衝高回落！恒指微漲0.2%，藥品股繼續活躍 大金融股多數低迷","url":"https://stock-news.laohu8.com/highlight/detail?id=2551715870","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551715870?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 12:00","pubTimestamp":1752552046,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6f73262067ecb7e28a3571ef8c288460","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06160","09618","03690","01810","01024","06978","06968","81024","399441","06030","TCEHY","09969","ALBmain","06881","03908","600030","HSCEI","00700","KSTmain","MCHmain","HTCD.SI","BIDU","METmain","TTTN","YANG","06099","HHImain","688235","01177","07226","601995","MIUmain","HSTECH","03383","01093","03086","600999","601881","MPNGY","MHImain","159992","HSI","JD","HSImain","161726","688428","BABA","ONC","TCHmain"],"gpt_icon":0},{"id":"2551134532","title":"30天通關！NMPA再掀審批革命","url":"https://stock-news.laohu8.com/highlight/detail?id=2551134532","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551134532?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 09:03","pubTimestamp":1752541434,"startTime":"0","endTime":"0","summary":"近期，NMPA发布《优化创新药临床试验审评审批有关事项》，提出将创新药临床试验默示许可的审评时限由60日压缩至30日。与NMPA推进的“临床快审批”形成合力，中国创新药正在迎来“研发—审批—支付”三位一体政策闭环的新格局。于中国药企而言，30日通道的设立无疑是一次重大制度红利。在美国，FDA自1997年起即实行IND 30天审评制，强调申报资料完整性、临床试验设计合理性及申办方资质。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715090641a6a9c704&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715090641a6a9c704&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","BK0239","06160"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-15","current":-76.118086,"percent":0.060284,"low":-89.808695,"twenty":-46.059796,"median":-39.216526,"eighty":-23.173462,"high":-19.234246,"avg":-39.781569,"sd":17.935645,"marketCap":29866148908},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-15","current":-76.118086,"twenty":-46.059796,"median":-39.216526,"eighty":-23.173462,"marketCap":29866148908}],"updateTime":1752732473467}}}